In February 2020, the German pharmaceutical company Bayer announced that it will outsource one part of its research to Nuvisan, which will affect 400 employees from Bayer's unit in Berlin. The outsourced research department focuses on small molecular agents. Details on the deal, which is expected to be finalised in mid-2020, have not been published. Nuvisan plans to take on all 400 employees from Bayer's unit.
Currently, Nuvisan has around 400 employees in Germany.